ADC偶联试剂盒(Tetrazine, DAR2&4, 1mg)

AGLink® ADC Conjugation Kit (Tetrazine, DAR2&4, 1mg) 

背景（Background）

抗体药物偶联物（ADC）是一种快速生长的抗癌药物。单克隆抗体通过化学连接体与细胞毒性有效载荷结合，该化学连接体指向癌症细胞表面表达的靶抗原，从而减少全身暴露并因此减少毒性。

AGLink®ADC偶联试剂盒旨在通过位点特异性酶反应将单克隆抗体与川芎嗪偶联。

应用说明（Application）

AGLink®ADC偶联试剂盒 (Tetrazine, DAR2&4, 1mg) 旨在通过位点特异性酶反应将1mg mAb与川芎嗪偶联。

该产品仅供科研使用。

优势特色（Features）

1.通过Fc聚糖进行位点特异性结合，结合效率高

2.均匀的DAR值和高度均匀的ADC产品

3.不需要氨基酸序列工程

4.易于使用：One-pot & One-step

5.两种选择：DAR2和DAR4 ADC产品

存储（Storage）

BoxA:未开封的试剂盒在≤-20℃的温度下可稳定储存12个月。打开的试剂盒应按照成分表存放。

BoxB: 未开封的试剂盒在4℃的温度下可稳定储存12个月。打开的试剂盒应按照成分表存放。

Statement of Rights

AGLink products are co-developed by ACROBiosystems Co., Ltd. and Glyco-therapy Biotechnology Co., Ltd. based on Glyco-therapy's conjugation platform (YTConju™) and are not authorized for commercial use. The sale and use of AGLink products doesn't represent any forms of license or authorization of the attached technologies for developing any diagnostic, therapeutic or prophylactic products for commercial purposes.

Note of application

AGLink products are intended for research use only by the Buyer or its users and can not be used for any other purposes, including, but not limited to, use for any clinical diagnostic type use, in vitro or in vivo therapeutic use, prophylactic use, any type of consumption or application to human or animals.